Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ted Drogendijk"'
Autor:
Philip, van Kerrebroeck, Christopher, Chapple, Ted, Drogendijk, Monique, Klaver, Roman, Sokol, Mark, Speakman, Klaudia, Traudtner, Marcus J, Drake, J, MacDermott
Publikováno v:
European urology, 64(6), 1003-1012. Elsevier
European Urology, 64(6), 1003-1012. Elsevier
European Urology, 64(6), 1003-1012. Elsevier
Background Storage symptoms are particularly bothersome in men with lower urinary tract symptoms (LUTS) but may not be adequately treated by α-blocker monotherapy. Objective To assess the efficacy and safety of a fixed-dose combination (FDC) of soli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ef5c958721716a9c66ecad3b6943d8f
https://doi.org/10.1016/j.eururo.2013.07.034
https://doi.org/10.1016/j.eururo.2013.07.034
Autor:
Marloes Schaddelee, Sjoerd van Marle, Hiromi Iitsuka, Nicole Grunenberg, Donna Kowalski, Marcel van Gelderen, John Meijer, Jennifer Lee, Charlotte Eltink, Virginie Kerbusch, Taiji Sawamoto, Hiroshi Matsushima, Ted Drogendijk, Wenhui Zhang, Selina Moy
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 50:838-850
Background and objectives Mirabegron is a potent and selective β3-adrenoceptor agonist in development for treatment of overactive bladder. Methods Mirabegron pharmacokinetics after single intravenous (i.v.) and oral doses, absolute bioavailability (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4444d0959535027ce74c069c16ca926e
https://doi.org/10.5414/cp201782
https://doi.org/10.5414/cp201782
Autor:
Linda, Cardozo, Elke, Hessdörfer, Rodolfo, Milani, Pedro, Arañó, Luc, Dewilde, Mark, Slack, Ted, Drogendijk, Mark, Wright, John, Bolodeoku, D M, Wright
Publikováno v:
BJU international, Vol. 102, no. 9, p. 1120-7 (2008)
OBJECTIVES: To examine the effects of the antimuscarinic agent solifenacin on urinary urgency, using a range of novel and established outcome measures, as urgency is the principal symptom of the overactive bladder syndrome (OAB). PATIENTS AND METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b695aaec92c871fef2cc488c3f70e48f
https://doi.org/10.1111/j.1464-410x.2008.07939.x
https://doi.org/10.1111/j.1464-410x.2008.07939.x
Autor:
Christopher R, Chapple, Marcus J, Drake, Philip, Van Kerrebroeck, Linda, Cardozo, Ted, Drogendijk, Monique, Klaver, Karin, Van Charldorp, Zalmai, Hakimi, Gerhard, Compion
Publikováno v:
BJU international. 113(5)
The term lower urinary tract symptoms (LUTS) encompasses a range of urinary symptoms, including storage symptoms (e.g. overactive bladder [OAB]) as well as voiding and post-micturition symptoms. Although treatment of male LUTS tends to focus on voidi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8ebeb9819e0bd2cfab7411a44ec82e26
https://pubmed.ncbi.nlm.nih.gov/24712917
https://pubmed.ncbi.nlm.nih.gov/24712917
Autor:
Chapple, Christopher R., Vladimir, Dvorak, Pjotr, Radziszewski, Philip Van Kerrebroeck, Jean Jacques Wyndaele, Brigitte, Bosman, Peter, Boerrigter, Ted, Drogendijk, Arwin, Ridder, Ingrid Van Der Putten Slob, Osamu, Yamaguchi, Carbone, Antonio
Publikováno v:
International urogynecology journal
International Urogynecology Journal, 24(9), 1447-1458. Springer-Verlag London Ltd.
International Urogynecology Journal
International Urogynecology Journal, 24(9), 1447-1458. Springer-Verlag London Ltd.
International Urogynecology Journal
Mirabegron is a potent and selective beta(3)-adrenoceptor agonist that may represent an alternative treatment option in place of antimuscarinics for patients with overactive bladder. Patients completed a single-blinded, 2-week placebo run-in period f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a4faceb17aa81a3f005dfb77a72fc9
https://hdl.handle.net/10067/1107320151162165141
https://hdl.handle.net/10067/1107320151162165141
Autor:
Charlotte, Eltink, Jennifer, Lee, Marloes, Schaddelee, Wenhui, Zhang, Virginie, Kerbusch, John, Meijer, Sjoerd, van Marle, Nicole, Grunenberg, Donna, Kowalski, Ted, Drogendijk, Selina, Moy, Hiromi, Iitsuka, Marcel, van Gelderen, Hiroshi, Matsushima, Taiji, Sawamoto
Publikováno v:
International journal of clinical pharmacology and therapeutics. 50(11)
Mirabegron is a potent and selective β3-adrenoceptor agonist in development for treatment of overactive bladder.Mirabegron pharmacokinetics after single intravenous (i.v.) and oral doses, absolute bioavailability (F), dose proportionality, sex diffe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ddff5de9c461fd4c3c06dbe5afebd160
https://pubmed.ncbi.nlm.nih.gov/22943933
https://pubmed.ncbi.nlm.nih.gov/22943933
Autor:
Vik Khullar, Gerard Amarenco, Javier C. Angulo, Javier Cambronero, Kjetil Høye, Ian Milsom, Piotr Radziszewski, Tomasz Rechberger, Peter Boerrigter, Ted Drogendijk, Marianne Wooning, Christopher Chapple
Publikováno v:
European urology. 63(2)
Mirabegron, a β(3)-adrenoceptor agonist, has been developed for the treatment of overactive bladder (OAB).To assess the efficacy and tolerability of mirabegron versus placebo.Multicenter randomised double-blind, parallel-group placebo- and tolterodi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::164bf382f025986c51db5a1f76f9ceef
https://pubmed.ncbi.nlm.nih.gov/23663617
https://pubmed.ncbi.nlm.nih.gov/23663617